Figure 2 | British Journal of Cancer

Figure 2

From: HER2 gene copy number status may influence clinical efficacy to anti-EGFR monoclonal antibodies in metastatic colorectal cancer patients

Figure 2

Patients’ distribution depending on HER2 gene status as detected by FISH. The detailed analysis of HER2 gene copy number allows to recognise different groups of tumours with distinct cytogenetic features. HER2-A=HER2 gene amplification (R:HER2/CEP17⩾ 2 in ⩾10% of the cells); HER2-all-A=HER2 gene amplification in all the sample (⩾90% of cells); HER2-CNG=HER2 gene copy number gain (presence of ⩾4 copies of the HER2 gene in ⩾40% of the cells); HER2-FISH+=HER2-A and HER2-CNG; HER2-FISH+*=HER2-FISH+ excluding HER2-all-A (i.e., HER2-CNG and HER2-minor-A); HER2-FISH−=absence of CNG and absence of HER2 amplification; HER2-minor-A=HER2 gene amplification in a minor population (10–60% of cells); HER2-non-A=absence of HER2 gene amplification; mCRC=metastatic colorectal cancer; wt=wild type.

Back to article page